CCA
TAK icon

Checchi Capital Advisers’s Takeda Pharmaceutical TAK Stock Holding History

Checchi Capital Advisers’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Sell
14,357
-234
-2% -$3.87K 0.01% 550
2026
Q1 		$270K Buy
14,591
+786
+6% +$13.8K 0.01% 495
2025
Q4 		$215K Sell
13,805
-385
-3% -$5.5K 0.01% 512
2025
Q3 		$208K Buy
14,190
+2,054
+17% +$30.5K 0.01% 532
2025
Q2 		$188K Buy
12,136
+224
+2% +$3.31K 0.01% 560
2025
Q1 		$177K Buy
+11,912
New +$167K 0.01% 566
2024
Q1 		– Sell
-12,746
Closed -$182K – 592
2023
Q4 		$182K Sell
12,746
-3,377
-21% -$47.9K 0.01% 535
2023
Q3 		$249K Buy
16,123
+1,633
+11% +$25.3K 0.02% 447
2023
Q2 		$228K Buy
14,490
+758
+6% +$12.4K 0.02% 502
2023
Q1 		$226K Sell
13,732
-41
-0.3% -$653 0.02% 502
2022
Q4 		$215K Sell
13,773
-136
-1% -$1.9K 0.02% 500
2022
Q3 		$180K Buy
13,909
+495
+4% +$6.88K 0.02% 522
2022
Q2 		$196K Buy
13,414
+447
+3% +$6.38K 0.02% 557
2022
Q1 		$186K Buy
12,967
+1,518
+13% +$22.3K 0.02% 529
2021
Q4 		$156K Sell
11,449
-5,614
-33% -$78.8K 0.01% 522
2021
Q3 		$279K Buy
17,063
+26
+0.2% +$436 0.03% 386
2021
Q2 		$287K Sell
17,037
-285
-2% -$4.85K 0.03% 387
2021
Q1 		$316K Buy
17,322
+13
+0.1% +$234 0.03% 340
2020
Q4 		$315K Sell
17,309
-2,733
-14% -$48K 0.03% 325
2020
Q3 		$358K Sell
20,042
-537
-3% -$9.78K 0.04% 263
2020
Q2 		$369K Buy
20,579
+937
+5% +$16.8K 0.04% 258
2020
Q1 		$298K Buy
19,642
+1,175
+6% +$21.3K 0.03% 252
2019
Q4 		$364K Buy
18,467
+3,990
+28% +$76.3K 0.05% 260
2019
Q3 		$249K Buy
14,477
+547
+4% +$9.46K 0.03% 338
2019
Q2 		$247K Sell
13,930
-2,302
-14% -$41.9K 0.03% 342
2019
Q1 		$331K Buy
+16,232
New +$327K 0.04% 270

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Checchi Capital Advisers's TAK Position: Q2 2026 in Review

Checchi Capital Advisers reduced its Takeda Pharmaceutical (TAK) stake by 1.6% in Q2 2026, selling an estimated $3.87K and leaving 14,357 shares worth $230K. The position accounts for 0.01% of the portfolio, ranked #550.

Checchi Capital Advisers first reported a position in TAK in Q1 2019 and has held it in 26 quarters since. The position peaked at $369K in Q2 2020. 379 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Checchi Capital Advisers held 14,357 shares of Takeda Pharmaceutical worth $230K as of Q2 2026.
  • Checchi Capital Advisers sold 234 Takeda Pharmaceutical shares in Q2 2026, an estimated $3.87K.
  • Takeda Pharmaceutical made up 0.01% of Checchi Capital Advisers's portfolio in Q2 2026, its #550 holding.
  • Checchi Capital Advisers first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 26 quarters since.
  • Checchi Capital Advisers's Takeda Pharmaceutical position peaked at $369K in Q2 2020.
  • 379 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Checchi Capital Advisers's 13F filing for Q2 2026, filed 4 Aug 2026.